Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders

World Journal of Gastroenterology

Volumn 20, Issue 11, 2014, Pages 2962-2970

  Yang, Deng Ho ^a,b   Ho, Ling Jun ^c   Lai, Jenn Haung ^d,e  

^a TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^e CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Autoantibody; Autoimmune; Biomarker; Cytokine; Hepatitis C virus

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY RF; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; CRYOGLOBULIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 6; NEUTROPHIL CYTOPLASMIC ANTIBODY; OSTEOPONTIN; RHEUMATOID FACTOR; SMOOTH MUSCLE ANTIBODY; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROID PEROXIDASE ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL FEATURE; DISEASE ASSOCIATION; GLOMERULONEPHRITIS; HEPATITIS C; HUMAN; LIVER FUNCTION; PATHOGENESIS; PREVALENCE; ANIMAL; AUTOIMMUNE DISEASES; BIOSYNTHESIS; BLOOD; COMPLICATION; IMMUNOLOGY;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; HEPATITIS C, CHRONIC; HUMANS;

EID: 84896481589     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i11.2962     Document Type: Article

References (92)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52 [PMID: 11439948 DOI: 10.1056/NEJM200107053450107]
2. Stefanova-Petrova DV, Tzvetanska AH, Naumova EJ, Mihailova AP, Hadjiev EA, Dikova RP, Vukov MI, Tchernev KG. Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol 2007; 13: 6518-6528 [PMID: 18161922]
3. Mohammed RH, ElMakhzangy HI, Gamal A, Mekky F, El Kassas M, Mohammed N, Abdel Hamid M, Esmat G. Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians. Clin Rheumatol 2010; 29: 1373-1380 [PMID: 20411290 DOI: 10.1007/s10067-010-1463-x]
4. Ramos-Casals M, Muñoz S, Medina F, Jara LJ, Rosas J, Calvo-Alen J, Brito-Zerón P, Forns X, Sánchez-Tapias JM. Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). J Rheumatol 2009; 36: 1442-1448 [PMID: 19369460 DOI: 10.3899/jrheum.080874]
5. Paroli M, Iannucci G, Accapezzato D. Hepatitis C virus infection and autoimmune diseases. Int J Gen Med 2012; 5: 903-907 [PMID: 23118549 DOI: 10.2147/IJGM.S37580]
6. Vergani D, Mieli-Vergani G. Autoimmune manifestations in viral hepatitis. Semin Immunopathol 2013; 35: 73-85 [PMID: 23010889 DOI: 10.1007/s00281-012-0328-6]
7. Luo JC, Hwang SJ, Li CP, Lu RH, Chan CY, Wu JC, Chang FY, Lee SD. Clinical significance of serum auto-antibodies in Chinese patients with chronic hepatitis C: negative role of serum viral titre and genotype. J Gastroenterol Hepatol 1998; 13: 475-479 [PMID: 9641643]
8. Ramos-Casals M, Font J, García-Carrasco M, Cervera R, Jiménez S, Trejo O, de la Red G, Sánchez-Tapias JM, Ingelmo M. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus. Arthritis Rheum 2000; 43: 2801-2806 [PMID: 11145039 DOI: 10.1002/1529-0131(200012)43:12<2801::AID-ANR21>3.0.CO;2-V]
9. Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. Lancet 2012; 379: 348-360 [PMID: 21868085 DOI: 10.1016/S0140-6736(11)60242-0]
10. Blackard JT, Kong L, Huber AK, Tomer Y. Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis. Thyroid 2013; 23: 863-870 [PMID: 23259732 DOI: 10.1089/thy.2012.0507]
11. Palazzi C, Buskila D, D'Angelo S, D'Amico E, Olivieri I. Autoantibodies in patients with chronic hepatitis C virus infection: pitfalls for the diagnosis of rheumatic diseases. Autoimmun Rev 2012; 11: 659-663 [PMID: 22155016 DOI: 10.1016/j.autrev.2011.11.011]
12. Saadoun D, Landau DA, Calabrese LH, Cacoub PP. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford) 2007; 46: 1234-1242 [PMID: 17566058 DOI: 10.1093/rheumatology/kem132]
13. Zhou Y, Lukes Y, Anderson J, Fileta B, Reinhardt B, Sjogren M. Hepatitis C virus E2 envelope protein induces dendritic cell maturation. J Viral Hepat 2007; 14: 849-858 [PMID: 1807028]
14. Sarobe P, Lasarte JJ, García N, Civeira MP, Borrás-Cuesta F, Prieto J. Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins. J Viral Hepat 2006; 13: 47-55 [PMID: 16364082]
15. Gómez CE, Perdiguero B, Cepeda MV, Mingorance L, García-Arriaza J, Vandermeeren A, Sorzano CÓ, Esteban M. High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome. J Virol 2013; 87: 7282-7300 [PMID: 23596307 DOI: 10.1128/JVI.03246-12]
16. Maillefert JF, Muller G, Falgarone G, Bour JB, Ratovohery D, Dougados M, Tavernier C, Breban M. Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis. Ann Rheum Dis 2002; 61: 635-637 [PMID: 12079907]
17. Hsu FC, Starkebaum G, Boyko EJ, Dominitz JA. Prevalence of rheumatoid arthritis and hepatitis C in those age 60 and older in a US population based study. J Rheumatol 2003; 30: 455-458 [PMID: 12610800]
18. Banks SE, Riley TR, Naides SJ. Musculoskeletal complaints and serum autoantibodies associated with chronic hepatitis C and nonalcoholic fatty liver disease. Dig Dis Sci 2007; 52: 1177-1182 [PMID: 17387612 DOI: 10.1007/s10620-006-9109-7]
19. Charles ED, Orloff MI, Nishiuchi E, Marukian S, Rice CM, Dustin LB. Somatic hypermutations confer rheumatoid factor activity in hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum 2013; 65: 2430-2440 [PMID: 23754128 DOI: 10.1002/art.38041]
20. Nowak U, Gill K, Skamene E, Newkirk MM. Rheumatoid factor induction in murine models of liver injury. Clin Exp Immunol 2007; 147: 324-329 [PMID: 17223974]
21. Toubi E, Zuckerman E, Kessel A, Rozenbaum M, Rosner I. IgA rheumatoid factor in patients with chronic HCV infection: prevalence and clinical correlations. Clin Exp Rheumatol 2003; 21: 524 [PMID: 12942711]
22. Agnello V, Elfahal M. Cryoglobulin types and rheumatoid factors associated with clinical manifestations in patients with hepatitis C virus infection. Dig Liver Dis 2007; 39 Suppl 1: S25-S31 [PMID: 17936219]
23. Riccio A, Conca P, Marzocchella C, Tarantino G. Rheumatoid factor after antiviral therapy in patients with HCV chronic hepatitis. Clin Exp Rheumatol 2008; 26: 926-928 [PMID: 19032831]
24. Zusinaite E, Metskula K, Salupere R. Autoantibodies and hepatitis C virus genotypes in chronic hepatitis C patients in Estonia. World J Gastroenterol 2005; 11: 488-491 [PMID: 15641131]
25. Chrétien P, Chousterman M, Abd Alsamad I, Ozenne V, Rosa I, Barrault C, Lons T, Hagège H. Non-organ-specific autoantibodies in chronic hepatitis C patients: association with histological activity and fibrosis. J Autoimmun 2009; 32: 201-205 [PMID: 19324518 DOI: 10.1016/j.jaut.2009.02.005]
26. Hsieh MY, Dai CY, Lee LP, Huang JF, Tsai WC, Hou NJ, Lin ZY, Chen SC, Wang LY, Chang WY, Chuang WL, Yu ML. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C. J Clin Pathol 2008; 61: 333-337 [PMID: 17545561]
27. Bai L, Feng ZR, Lu HY, Li WG, Yu M, Xu XY. Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China. Chin Med J (Engl) 2009; 122: 5-9 [PMID: 19187609]
28. Chen CH, Lee CM, Chen CH, Hu TH, Wang JH, Hung CH, Chung CH, Lu SN. Prevalence and clinical relevance of serum autoantibodies in patients with chronic hepatitis C. Chang Gung Med J 2010; 33: 258-265 [PMID: 20584503]
29. Himoto T, Nakai S, Kinekawa F, Yoneyama H, Deguchi A, Kurokochi K, Masaki T, Senda S, Haba R, Watanabe S, Nishioka M, Kuriyama S. Clinical characteristics of patients with hepatitis C virus-related chronic liver disease seropositive for anticentromere antibody. Dig Dis Sci 2009; 54: 360-368 [PMID: 18629643 DOI: 10.1007/s10620-008-0359-y]
30. Narciso-Schiavon JL, Freire FC, Suarez MM, Ferrari MV, Scanhola GQ, de Schiavon LL, de Carvalho Filho RJ, Ferraz ML, Silva AE. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon? Eur J Gastroenterol Hepatol 2009; 21: 440-446 [PMID: 19382301]
31. Hsieh MY, Dai CY, Lee LP, Huang JF, Chuang WL, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Yu ML. Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients. Kaohsiung J Med Sci 2012; 28: 86-93 [PMID: 22313535 DOI: 10.1016/j.kjms.2011.10.031]
32. Khairy M, El-Raziky M, El-Akel W, Abdelbary MS, Khatab H, El-Kholy B, Esmat G, Mabrouk M. Serum autoantibodies positivity prevalence in patients with chronic HCV and impact on pegylated interferon and ribavirin treatment response. Liver Int 2013; 33: 1504-1509 [PMID: 23763380 DOI: 10.1111/liv.12227]
33. Santer DM, Ma MM, Hockman D, Landi A, Tyrrell DL, Houghton M. Enhanced activation of memory, but not naïve, B cells in chronic hepatitis C virus-infected patients with cryoglobulinemia and advanced liver fibrosis. PLoS One 2013; 8: e68308 [PMID: 23840845 DOI: 10.1371/journal.pone.0068308]
34. Sansonno D, Carbone A, De Re V, Dammacco F. Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology (Oxford) 2007; 46: 572-578 [PMID: 17317717]
35. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. Kidney Int 2009; 76: 818-824 [PMID: 19606079 DOI: 10.1038/ki.2009.247]
36. Andrade LJ, Melo PR, Atta AM, Atta ML, Jesus LS, Sousa GM, Silva CA, Paraná R. Smooth muscle antibodies and cryoglobulinemia are associated with advanced liver fibrosis in Brazilian hepatitis C virus carriers. Braz J Infect Dis 2011; 15: 66-68 [PMID: 21412592]
37. Barra L, Pope J, Bessette L, Haraoui B, Bykerk V. Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. Rheumatology (Oxford) 2011; 50: 311-316 [PMID: 20621983 DOI: 10.1093/rheumatology/keq190]
38. Baka Z, György B, Géher P, Buzás EI, Falus A, Nagy G. Citrullination under physiological and pathological conditions. Joint Bone Spine 2012; 79: 431-436 [PMID: 22366145 DOI: 10.1016/j.jbspin.2012.01.008]
39. Szodoray P, Szabó Z, Kapitány A, Gyetvai A, Lakos G, Szántó S, Szücs G, Szekanecz Z. Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2010; 9: 140-143 [PMID: 19427413 DOI: 10.1016/j.autrev.2009.04.006]
40. Wiik AS, van Venrooij WJ, Pruijn GJ. All you wanted to know about anti-CCP but were afraid to ask. Autoimmun Rev 2010; 10: 90-93 [PMID: 20727426 DOI: 10.1016/j.autrev.2010.08.009]
41. Lu MC, Hsieh SC, Lai NS, Li KJ, Wu CH, Yu CL. Comparison of anti-agalactosyl IgG antibodies, rheumatoid factors, and anti-cyclic citrullinated peptide antibodies in the differential diagnosis of rheumatoid arthritis and its mimics. Clin Exp Rheumatol 2007; 25: 716-721 [PMID: 18078619]
42. Orge E, Cefle A, Yazici A, Gürel-Polat N, Hulagu S. The positivity of rheumatoid factor and anti-cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection. Rheumatol Int 2010; 30: 485-488 [PMID: 19547976 DOI: 10.1007/s00296-009-0997-1]
43. Ezzat WM, Raslan HM, Aly AA, Emara NA, El Menyawi MM, Edrees A. Anti-cyclic citrullinated peptide antibodies as a discriminating marker between rheumatoid arthritis and chronic hepatitis C-related polyarthropathy. Rheumatol Int 2011; 31: 65-69 [PMID: 19882340 DOI: 10.1007/s00296-009-1225-8]
44. Liu FC, Chao YC, Hou TY, Chen HC, Shyu RY, Hsieh TY, Chen CH, Chang DM, Lai JH. Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia. Clin Rheumatol 2008; 27: 463-467 [PMID: 17876647 DOI: 10.1007/s10067-007-0729-4]
45. Palazzi C, D'Angelo S, Olivieri I. Hepatitis C virus-related arthritis. Autoimmun Rev 2008; 8: 48-51 [PMID: 18707027 DOI: 10.1016/j.autrev.2008.07.025]
46. Jorgensen C, Legouffe MC, Perney P, Coste J, Tissot B, Segarra C, Bologna C, Bourrat L, Combe B, Blanc F, Sany J. Sicca syndrome associated with hepatitis C virus infection. Arthritis Rheum 1996; 39: 1166-1171 [PMID: 8670326]
47. Lormeau C, Falgarone G, Roulot D, Boissier MC. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine 2006; 73: 633-638 [PMID: 17056293]
48. Carrozzo M. Oral diseases associated with hepatitis C virus infection. Part 1. sialadenitis and salivary glands lymphoma. Oral Dis 2008; 14: 123-130 [PMID: 18208477 DOI: 10.1111/j.1601-0825.2007.01436.x]
49. Ceribelli A, Cavazzana I, Cattaneo R, Franceschini F. Hepatitis C virus infection and primary Sjögren's syndrome: a clinical and serologic description of 9 patients. Autoimmun Rev 2008; 8: 92-94 [PMID: 18692602 DOI: 10.1016/j.autrev.2008.07.003]
50. Dalekos GN, Kistis KG, Boumba DS, Voulgari P, Zervou EK, Drosos AA, Tsianos EV. Increased incidence of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti-phospholipid syndrome. Eur J Gastroenterol Hepatol 2000; 12: 67-74 [PMID: 10656213]
51. Zachou K, Liaskos C, Christodoulou DK, Kardasi M, Papadamou G, Gatselis N, Georgiadou SP, Tsianos EV, Dalekos GN. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest 2003; 33: 161-168 [PMID: 12588291]
52. Muñoz-Rodríguez FJ, Tàssies D, Font J, Reverter JC, Cervera R, Sánchez-Tapias JM, Mazzara R, Ordinas A, Ingelmo M. Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome. J Hepatol 1999; 30: 770-773 [PMID: 10365800]
53. Matsuda J, Saitoh N, Gotoh M, Gohchi K, Tsukamoto M, Syoji S, Miyake K, Yamanaka M. High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol 1995; 90: 1138-1141 [PMID: 7611213]
54. Badiani RG, Becker V, Perez RM, Matos CA, Lemos LB, Lanzoni VP, Andrade LE, Dellavance A, Silva AE, Ferraz ML. Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis? World J Gastroenterol 2010; 16: 3704-3708 [PMID: 20677344]
55. Ferri S, Muratori L, Quarneti C, Muratori P, Menichella R, Pappas G, Granito A, Ballardini G, Bianchi FB, Lenzi M. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. J Hepatol 2009; 50: 1093-1101 [PMID: 19398235 DOI: 10.1016/j.jhep.2009.02.020]
56. Mauss S, Berger F, Schober A, Moog G, Heyne R, John C, Pape S, Hueppe D, Pfeiffer-Vornkahl H, Alshuth U. Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome. J Viral Hepat 2013; 20: e72-e77 [PMID: 23490392 DOI: 10.1111/jvh.12011]
57. Lamprecht P, Gutzeit O, Csernok E, Gause A, Longombardo G, Zignego AL, Gross WL, Ferri C. Prevalence of ANCA in mixed cryoglobulinemia and chronic hepatitis C virus infection. Clin Exp Rheumatol 2003; 21: S89-S94 [PMID: 14740433]
58. Cojocaru M, Cojocaru IM, Iacob SA. Prevalence of anti-neutrophil cytoplasmic antibodies in patients with chronic hepatitis C infection associated mixed cryoglobulinemia. Rom J Intern Med 2006; 44: 427-431 [PMID: 18386619]
59. Chen M, Kallenberg CG. ANCA-associated vasculitides--advances in pathogenesis and treatment. Nat Rev Rheumatol 2010; 6: 653-664 [PMID: 20924413 DOI: 10.1038/nrrheum.2010.158]
60. Bonaci-Nikolic B, Andrejevic S, Pavlovic M, Dimcic Z, Ivanovic B, Nikolic M. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge. Clin Rheumatol 2010; 29: 893-904 [PMID: 20306213 DOI: 10.1007/s10067-010-1424-4]
61. Wu YY, Hsu TC, Chen TY, Liu TC, Liu GY, Lee YJ, Tsay GJ. Proteinase 3 and dihydrolipoamide dehydrogenase (E3) are major autoantigens in hepatitis C virus (HCV) infection. Clin Exp Immunol 2002; 128: 347-352 [PMID: 11985526]
62. Shahin AA, El Desouky SM, Zayed HS. A retrospective analysis of treatment outcomes in patients with hepatitis C related systemic vasculitis receiving intravenous methylprednisolone and cyclophosphamide. Clin Rheumatol 2011; 30: 607-614 [PMID: 20924628 DOI: 10.1007/s10067-010-1582-4]
63. Ploix C, Verber S, Chevallier-Queyron P, Ritter J, Bousset G, Monier JC, Fabien N. Hepatitis C virus infection is frequently associated with high titers of anti-thyroid antibodies. Int J Immunopathol Pharmacol 1999; 12: 121-126 [PMID: 12783639]
64. Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, Marchi S, Ferrannini E. Thyroid disorders in chronic hepatitis C. Am J Med 2004; 117: 10-13 [PMID: 15210382 DOI: 10.1016/j.amjmed.2004.01.023]
65. Yang R, Shan Z, Li Y, Fan C, Li C, Teng W. Prevalence of thyroid autoantibodies in hepatitis C and hepatitis B infection in China. Intern Med 2011; 50: 811-815 [PMID: 21498927]
66. Mohran ZY, Abdel Kader NA, Abdel Moez AT, Abbas AA. Subclinical autoimmune thyroid disorders in Egyptian patients with untreated chronic hepatitis C virus infection. J Egypt Soc Parasitol 2010; 40: 45-56 [PMID: 20503585]
67. Nair Kesavachandran C, Haamann F, Nienhaus A. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One 2013; 8: e55364 [PMID: 23383326 DOI: 10.1371/journal.pone.0055364]
68. Teng ZL, Gong WJ, Zhang SQ, Sun YX, Ma XH. Clinical observation of hashimoto thyroiditis in patients with chronic hepatitis C undergoing pegylated-interferon alpha-2a and ribavirin combination therapy. Zhonghua Ganzangbing Zazhi 2013; 21: 101-104 [PMID: 23663880 DOI: 10.3760/cma.j.issn.1007-3418.2013.02.007]
69. Gehring S, Kullmer U, Koeppelmann S, Gerner P, Wintermeyer P, Wirth S. Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha. World J Gastroenterol 2006; 12: 5787-5792 [PMID: 17007043]
70. Kajiyama Y, Kikuchi K, Takai A, Hosoya N, Hoshino H, Hino K, Miyakawa H. B-cell-activating factor affects the occurrence of thyroid autoimmunity in chronic hepatitis C patients treated with interferon alpha. Clin Dev Immunol 2012; 2012: 247973 [PMID: 22481965 DOI: 10.1155/2012/247973]
71. Shao C, Huo N, Zhao L, Gao Y, Fan X, Zheng Y, Wang L, Lu H, Xu X, Guo X. The presence of thyroid peroxidase antibody of IgG2 subclass is a risk factor for thyroid dysfunction in chronic hepatitis C patients. Eur J Endocrinol 2013; 168: 717-722 [PMID: 23419250 DOI: 10.1530/EJE-12-0775]
72. Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res 2013; 56: 131-142 [PMID: 23371836 DOI: 10.1007/s12026-013-8384-0]
73. Cervoni JP, Thévenot T, Weil D, Muel E, Barbot O, Sheppard F, Monnet E, Di Martino V. C-reactive protein predicts short-term mortality in patients with cirrhosis. J Hepatol 2012; 56: 1299-1304 [PMID: 22314431 DOI: 10.1016/j.jhep.2011.12.030]
74. Kessel A, Elias G, Pavlotzky E, Zuckerman E, Rosner I, Toubi E. Anti-C-reactive protein antibodies in chronic hepatitis C infection: correlation with severity and autoimmunity. Hum Immunol 2007; 68: 844-848 [PMID: 17961773]
75. Sjöwall C, Cardell K, Boström EA, Bokarewa MI, Enocsson H, Ekstedt M, Lindvall L, Frydén A, Almer S. High prevalence of autoantibodies to C-reactive protein in patients with chronic hepatitis C infection: association with liver fibrosis and portal inflammation. Hum Immunol 2012; 73: 382-388 [PMID: 22333691 DOI: 10.1016/j.humimm.2012.01.009]
76. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-137 [PMID: 9441573]
77. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22: 347-352 [PMID: 20410258 DOI: 10.1093/intimm/dxq030]
78. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Marchi S, Colaci M, Bruschi F, Fallahi P. High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia. Clin Rheumatol 2009; 28: 1179-1185 [PMID: 19543846 DOI: 10.1007/s10067-009-1218-8]
79. Antonelli A, Ferri C, Ferrari SM, Di Domenicantonio A, Ferrari P, Pupilli C, Nicolini A, Zignego AL, Marchi S, Fallahi P. The presence of autoimmune thyroiditis in mixed cryoglobulinemia patients is associated with high levels of circulating interleukin-6, but not of tumor necrosis factor-alpha. Clin Exp Rheumatol 2011; 29: S17-S22 [PMID: 21385538]
80. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Goglia F, Pampana A, Bruschi F, Fallahi P. Serum levels of proinflammatory cytokines interleukin-1beta, interleukin-6, and tumor necrosis factor alpha in mixed cryoglobulinemia. Arthritis Rheum 2009; 60: 3841-3847 [PMID: 19950277 DOI: 10.1002/art.25003]
81. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 1998; 187: 2009-2021 [PMID: 9625760]
82. Cox MA, Jenh CH, Gonsiorek W, Fine J, Narula SK, Zavodny PJ, Hipkin RW. Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol 2001; 59: 707-715 [PMID: 11259614]
83. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Sebastiani M, Franzoni F, Galetta F, Ferrannini E. High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis. Cytokine 2008; 42: 137-143 [PMID: 18282714 DOI: 10.1016/j.cyto.2008.01.002]
84. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Sebastiani M, Ferrari D, Giunti M, Frascerra S, Tolari S, Franzoni F, Galetta F, Marchi S, Ferrannini E. High values of CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. Am J Gastroenterol 2008; 103: 2488-2494 [PMID: 18775023 DOI: 10.1111/j.1572-0241.2008.02040.x]
85. Antonelli A, Ferri C, Ferrari SM, De Marco S, Di Domenicantonio A, Centanni M, Pupilli C, Villa E, Menichetti F, Fallahi P. Interleukin-1β, C-x-C motif ligand 10, and interferon-gamma serum levels in mixed cryoglobulinemia with or without autoimmune thyroiditis. J Interferon Cytokine Res 2010; 30: 835-842 [PMID: 20929277 DOI: 10.1089/jir.2010.0024]
86. Antonelli A, Ferri C, Ferrari SM, Ghiri E, Marchi S, Sebastiani M, Fallahi P. Serum concentrations of interleukin 1beta, CXCL10, and interferon-gamma in mixed cryoglobulinemia associated with hepatitis C infection. J Rheumatol 2010; 37: 91-97 [PMID: 19918044 DOI: 10.3899/jrheum.090246]
87. Antonelli A, Fallahi P, Ferrari SM, Sebastiani M, Manfredi A, Mazzi V, Fabiani S, Centanni M, Marchi S, Ferri C. Circulating CXCL11 and CXCL10 are increased in hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. Mod Rheumatol 2012; 22: 659-667 [PMID: 22160826 DOI: 10.1007/s10165-011-0565-x]
88. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008; 19: 333-345 [PMID: 18952487 DOI: 10.1016/j.cytogfr.2008.08.001]
89. Pedraza CE, Nikolcheva LG, Kaartinen MT, Barralet JE, McKee MD. Osteopontin functions as an opsonin and facilitates phagocytosis by macrophages of hydroxyapatite-coated microspheres: implications for bone wound healing. Bone 2008; 43: 708-716 [PMID: 18656563 DOI: 10.1016/j.bone.2008.06.010]
90. Zhao L, Li T, Wang Y, Pan Y, Ning H, Hui X, Xie H, Wang J, Han Y, Liu Z, Fan D. Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection. Int J Clin Pract 2008; 62: 1056-1062 [PMID: 17537188]
91. Bassyouni IH, Bassyouni RH, Ibrahim NH, Soliman AF. Elevated serum osteopontin levels in chronic hepatitis C virus infection: association with autoimmune rheumatologic manifestations. J Clin Immunol 2012; 32: 1262-1269 [PMID: 22730056 DOI: 10.1007/s10875-012-9727-7]
92. Libra M, Indelicato M, De Re V, Zignego AL, Chiocchetti A, Malaponte G, Dianzani U, Nicoletti F, Stivala F, McCubrey JA, Mazzarino MC. Elevated Serum Levels of Osteopontin in HCV-Associated Lymphoproliferative Disorders. Cancer Biol Ther 2005; 4: 1192-1194 [PMID: 16177564]